Evidence for lipid peroxidation in obstructive sleep apnea.

STUDY OBJECTIVES Obstructive sleep apnea syndrome (OSA) is associated with an increased rate of cardiovascular morbidity, which has been suggested to be related to oxidative stress. The present study investigated the concentration of lipid peroxidation biomarkers in patients with OSA in comparison with nonapneic controls and the effects of treatment with nasal continuous positive airway pressure (nCPAP) on these biomarkers. DESIGN In Experiment 1, morning plasma levels of the oxidative-stress biomarkers, thiobarbituric reactive substances (TBARS) and peroxides (PD), and of the antioxidant protective enzyme paraxonase-1 (PON1), were measured in OSA patients with and without cardiovascular disease (CVD) and in nonapneic controls after an overnight fasting. The concentrations of the biomarkers were compared between patients and controls and were correlated with respiratory disturbance index (RDI). In Experiment 2, TBARS and PD were measured at hourly intervals during sleep in sleep-apnea patients before and after nCPAP treatment as well as in controls. PATIENTS In the first experiment, 114 consecutive patients with sleep apnea, 55 without (+OSA/-CVD) and 59 with CVD (+OSA/+CVD), and 30 nonapneic controls were investigated. Nine patients and 6 controls participated in Experiment 2. Five of the patients were also studied 9.3 +/- 3.9 months after nCPAP treatment. MEASUREMENTS AND RESULTS Morning levels of TBARS and PD were found to be significantly higher in both groups of OSA patients than in controls. The PON1 was lower in +OSA/+CVD patients than in controls and +OSA/-CVD patients, but the difference between the 2 OSA groups bordered on statistical significance. The concentrations of TBARS and PD were significantly positively correlated with RDI (.43, P < .0001 and .36, P < .0002, respectively), while a negative correlation was found between RDI and PON1 activity (-.24, P < .01). Stepwise regression analysis revealed that RDI was an independent significant predictor of all 3 lipid-peroxidation biomarkers. In the second experiment, nocturnal levels of TBARS and PD were significantly higher in sleep-apnea patients than in controls and were significantly lowered by nCPAP treatment. CONCLUSIONS These results support the existence of an increased state of oxidative stress in OSA and its possible involvement in cardiovascular morbidity.

[1]  A. Agustí,et al.  Abnormal lipid peroxidation in patients with sleep apnoea. , 2000, The European respiratory journal.

[2]  L. Lavie,et al.  Obstructive sleep apnoea syndrome--an oxidative stress disorder. , 2003, Sleep medicine reviews.

[3]  P. Lavie,et al.  Plasma levels of nitric oxide and L-arginine in sleep apnea patients , 2003, Journal of Molecular Neuroscience.

[4]  T. Young,et al.  Prospective study of the association between sleep-disordered breathing and hypertension. , 2000, The New England journal of medicine.

[5]  H. Esterbauer,et al.  A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. , 1989, Journal of lipid research.

[6]  P. Lavie,et al.  Phenotypic and Functional Characterization of Blood γδ T Cells in Sleep Apnea , 2003 .

[7]  W. Seeger,et al.  Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy , 2000, Thorax.

[8]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[9]  H. Esterbauer,et al.  Methods to determine oxidation of low-density lipoproteins. , 1994, Methods in enzymology.

[10]  W K Lam,et al.  Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. , 2000, American journal of respiratory and critical care medicine.

[11]  E. Anggard,et al.  Formation of PGF2-isoprostanes during the oxidative modification of low density lipoprotein. , 1994, Biochemical and biophysical research communications.

[12]  M. Jahangiri,et al.  Elevated plasma lipid hydroperoxides in patients with coronary artery disease. , 1997, American heart journal.

[13]  P. Lavie,et al.  Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. , 1999, Journal of the American College of Cardiology.

[14]  W. Seeger,et al.  Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. , 2000, American journal of respiratory and critical care medicine.

[15]  J. Hedner,et al.  Increased vasoconstrictor sensitivity in obstructive sleep apnea. , 2000, Journal of applied physiology.

[16]  J. McCord,et al.  Oxygen-derived free radicals in postischemic tissue injury. , 1985, The New England journal of medicine.

[17]  Peretz Lavie,et al.  Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study , 2000, BMJ : British Medical Journal.

[18]  R. Browne,et al.  The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds related to oxidative stress as applied to the clinical chemistry laboratory. , 1994, Advances in experimental medicine and biology.

[19]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[20]  V. Somers,et al.  Impairment of Endothelium-Dependent Vasodilation of Resistance Vessels in Patients With Obstructive Sleep Apnea , 2000, Circulation.

[21]  A. Smolen,et al.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[22]  P. Lavie,et al.  Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome. , 2003, Sleep.

[23]  C. Zwillich,et al.  Possible atherogenic effects of hypoxia during obstructive sleep apnea. , 1993, Sleep.

[24]  A. Kuksis,et al.  Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. , 2003, Cardiovascular research.

[25]  P. Lavie,et al.  Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. , 2001, Chest.

[26]  T. Lehtimäki,et al.  Autoantibodies against Oxidised Low-Density Lipoprotein in Patients with Obstructive Sleep Apnoea , 1999, Clinical chemistry and laboratory medicine.

[27]  A. Mangoni,et al.  Homocysteine and cardiovascular disease: current evidence and future prospects. , 2002, The American journal of medicine.

[28]  P. Winocour,et al.  Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.

[29]  W. Lands,et al.  Iodometric measurement of lipid hydroperoxides in human plasma. , 1991, Analytical biochemistry.

[30]  P. Lavie,et al.  Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. , 2002, American journal of respiratory and critical care medicine.

[31]  M. Aviram,et al.  Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. , 2000, Circulation.

[32]  M. Stringer,et al.  Lipid peroxides and atherosclerosis. , 1989, BMJ.

[33]  U. Beisiegel,et al.  Whole plasma oxidation assay as a measure of lipoprotein oxidizability , 1997, BioFactors.

[34]  R. Ross.  Atherosclerosis is an inflammatory disease , 1999 .

[35]  P. Durrington,et al.  Paraoxonase and Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[36]  T. Rabben,et al.  Sleep-disordered breathing in men with coronary artery disease. , 1996, Chest.

[37]  M. Kryger,et al.  Susceptibility of LDL to oxidative stress in obstructive sleep apnea. , 1998, Sleep.

[38]  Farris K. Timimi,et al.  Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. , 1997, Circulation.

[39]  S. Aust,et al.  Microsomal lipid peroxidation. , 1978, Methods in enzymology.

[40]  J. Hedner,et al.  Impairment of vascular endothelial function and left ventricular filling : association with the severity of apnea-induced hypoxemia during sleep. , 2001, Chest.

[41]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[42]  S. Gariballa,et al.  Antioxidant capacity after acute ischaemic stroke. , 2002, QJM : monthly journal of the Association of Physicians.

[43]  Jeetesh V. Patel,et al.  Serum paraoxonase after myocardial infarction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[44]  H. Ohlin,et al.  Transient release of lipid peroxidation products as a non-invasive marker of successful reperfusion after thrombolysis for myocardial infarction. , 1995, British heart journal.

[45]  C. Kunsch,et al.  Oxidative stress as a regulator of gene expression in the vasculature. , 1999, Circulation research.